Omaveloxolone Capsules, 300 mg ( DrugBank: Omaveloxolone )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
18脊髄小脳変性症(多系統萎縮症を除く。)1

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 76 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02255435
(ClinicalTrials.gov)
January 201530/9/2014RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIeA Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)Friedreich AtaxiaDrug: Omaveloxolone Capsules, 2.5 mg;Drug: Omaveloxolone Capsules, 5 mg;Drug: Omaveloxolone Capsules, 10 mg;Drug: Placebo;Drug: Omaveloxolone Capsules, 20 mg;Drug: Omaveloxolone Capsules, 40 mg;Drug: Omaveloxolone Capsules, 80 mg;Drug: Omaveloxolone Capsules, 160 mg;Drug: Omaveloxolone Capsules, 300 mg;Drug: Omaveloxolone Capsules, 150 mgReata Pharmaceuticals, Inc.AbbVie;Friedreich's Ataxia Research AllianceActive, not recruiting16 Years40 YearsAll172Phase 2United States;Australia;Austria;Italy;United Kingdom;Brazil